Patents Assigned to Nippon Chemiphar Co., Ltd.
  • Patent number: 10413546
    Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 17, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NIPPON MEDICAL SCHOOL FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Takeshi Nishino, Shinsuke Kato, Masako Kato, Hidenori Suzuki, Ken Okamoto
  • Publication number: 20190255022
    Abstract: A wound-healing agent is provided by using a benzisoxazole compound represented by the following general formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, a solvate of any of the foregoing, or the like, which exerts a PPAR? agonist effect.
    Type: Application
    Filed: May 11, 2017
    Publication date: August 22, 2019
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Toshitake HIRAI, Takaichi HAMANO, Tomio YAMAKAWA
  • Publication number: 20190192510
    Abstract: A compound represented by the following formula (I) or the formula (II) disclosed in the specification is a GPR119 agonist, and is used as an agent for treating diabetes: wherein one of T1, T2, T3, and T4 is N, and each of the other three independently is CR4 or, in the alternative, each of the four independently is CR4; each of R2 and R3 is hydrogen or a C1-8 alkyl group; the double line consisting of a solid line and a broken line means a single or double bond; A is (CH2)m, a bond, or the like; B is (C(R5)H)n, a bond, or the like; one of U and V is N, and the other is CR7; W is C or CR8; each of X and Y is a C1-3 alkylene group, which optionally has a halogen atom, hydroxyl etc.; Z is C(O)OR9, C(O)R10, or the like.
    Type: Application
    Filed: February 1, 2011
    Publication date: June 27, 2019
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Tsuyoshi ENDO, Rie TAKAHASHI, Hiroto TANAKA, Toshihiro KUNIGAMI
  • Patent number: 10292974
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 21, 2019
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Publication number: 20190077767
    Abstract: A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each repres
    Type: Application
    Filed: January 12, 2017
    Publication date: March 14, 2019
    Applicants: Nippon Chemiphar Co., Ltd., Kinki University
    Inventors: Hiroto TANAKA, Isao OOI, Yuzo MOGI, Masaaki HIROSE, Tsuyoshi ENDO, Toru OGAWA, Atsufumi KAWABATA
  • Patent number: 10173990
    Abstract: Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 8, 2019
    Assignees: Nippon Chemiphar Co., Ltd., J-Pharma Co., Ltd., DeThree Res. Lab. Inc.
    Inventors: Tsuyoshi Endo, Kunio Kobayashi, Hiroto Tanaka, Daisuke Saito, Masuharu Hirano, Hitoshi Endou, Naohiko Anzai
  • Patent number: 10150744
    Abstract: The present invention relates to a compound represented by the following general formula (I), which has a P2X4 receptor antagonistic activity (in the formula, R1, R2 and R3 represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, and the like, X represents C or N, Y represents N or C(?O), provided that when X is C, Y represents N, and when X is N, Y represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, n represents an integer of 0 to 6, Z represents O, S, or an atomic bond, and A represents benzene ring, pyridine ring, and the like).
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 11, 2018
    Assignees: NIPPON CHEMIPHAR CO., LTD, KYUSHU UNIVERSITY
    Inventors: Shogo Sakuma, Kunio Kobayashi, Masatoshi Ushioda, Toshiyasu Imai, Kazuhide Inoue
  • Publication number: 20180319752
    Abstract: Compounds represented by the following general formula (I), which has a P2X4 receptor antagonistic activity (in the formula, R1, R2 and R3 represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, and the like, X represents C or N, Y represents N or C(?O), provided that when X is C, Y represents N, and when X is N, Y represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, n represents an integer of 0 to 6, Z represents O, S, or an atomic bond, and A represents benzene ring, pyridine ring, and the like).
    Type: Application
    Filed: July 19, 2018
    Publication date: November 8, 2018
    Applicants: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY
    Inventors: Shogo SAKUMA, Kunio KOBAYASHI, Masatoshi USHIODA, Toshiyasu IMAI, Kazuhide INOUE
  • Publication number: 20180201587
    Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 19, 2018
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Masatoshi USHIODA, Kunio KOBAYASHI, Daisuke SAITO, Shogo SAKUMA, Toshiyasu IMAI, Kazuhide INOUE
  • Patent number: 9969700
    Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 15, 2018
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Masatoshi Ushioda, Kunio Kobayashi, Daisuke Saito, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
  • Patent number: 9963460
    Abstract: A morphinan derivative represented by the following formula (I), a tautomer or a stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a medicament, an analgesic and an antipruritic drug including the same as an active ingredient: wherein R is selected from hydrogen and C1-6 alkyl, and n represents an integer of 0 to 2.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: May 8, 2018
    Assignees: University of Tsukuba, Nippon Chemiphar Co., Ltd.
    Inventors: Hiroshi Nagase, Naoshi Yamamoto
  • Publication number: 20180117047
    Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.
    Type: Application
    Filed: February 23, 2016
    Publication date: May 3, 2018
    Applicants: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NIPPON MEDICAL SCHOOL FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Takeshi NISHINO, Shinsuke KATO, Masako KATO, Hidenori SUZUKI, Ken OKAMOTO
  • Publication number: 20180057493
    Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 1, 2018
    Applicants: UNIVERSITY OF TSUKUBA, SCHOOL JURIDICAL PERSON KITASATO INSTITUTE, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Patent number: 9873683
    Abstract: The present invention relates to a compound represented by the following general formula (II), wherein, in the formula, R1a to R6a represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, and the like, Xa represents C or N, Ya represents N or C(?O), provided that when Xa is C, Ya represents N, and when Xa is N, Ya represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, Aa represents benzene ring, pyridine ring, and the like, Da represents tetrazole ring, imidazole ring, and the like, Ea represents —(CR9aR10a)p-Ta-, and Ga represents benzene ring, pyridine ring, and the like, which has a P2X4 receptor antagonistic activity.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: January 23, 2018
    Assignees: NIPPON CHEMIPHAR CO., LTD, KYUSHU UNIVERSITY
    Inventors: Shogo Sakuma, Kunio Kobayashi, Masatoshi Ushioda, Daisuke Saito, Toshiyasu Imai, Kazuhide Inoue
  • Patent number: 9840497
    Abstract: The present invention relates to a compound represented by the following general formula (II), wherein, in the formula, R1a to R6a represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, and the like, Xa represents C or N, Ya represents N or C(?O), provided that when Xa is C, Ya represents N, and when Xa is N, Ya represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, Aa represents benzene ring, pyridine ring, and the like, Da represents tetrazole ring, imidazole ring, and the like, Ea represents —(CR9aR10a)p-Ta-, and Ga represents benzene ring, pyridine ring, and the like, which has a P2X4 receptor antagonistic activity.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 12, 2017
    Assignees: NIPPON CHEMIPHAR CO., LTD, KYUSHU UNIVERSITY
    Inventors: Shogo Sakuma, Kunio Kobayashi, Masatoshi Ushioda, Daisuke Saito, Toshiyasu Imai, Kazuhide Inoue
  • Patent number: 9624223
    Abstract: The present invention relates to a morphinan derivative represented by the following general formula (I), wherein R1 represents hydrogen, C1-6 alkyl, C6-10 aryl, etc., R2 and R3, which are the same or different, represent hydrogen, hydroxy, etc., R4 and R5 represent hydrogen, C1-6 alkyl, etc., R6 represents hydrogen, hydroxy, C1-6 alkyl, etc., X represents O or CH2, Y represents C?O, C(?O)O, etc., and m and n, which are the same or different, represent an integer of 0 to 2 (m and n are not 0 at the same time), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as an analgesic, antianxiety drug, etc. containing the same as an active ingredient.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: April 18, 2017
    Assignees: THE KITASATO INSTITUTE, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Hideaki Fujii, Eriko Nakata, Yoshikazu Watanabe, Daisuke Saito, Toshihiro Takahashi
  • Publication number: 20170081294
    Abstract: The present invention relates to a compound represented by the following general formula (I), which has a P2X4 receptor antagonistic activity (in the formula, R1, R2 and R3 represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, and the like, X represents C or N, Y represents N or C(?O), provided that when X is C, Y represents N, and when X is N, Y represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, n represents an integer of 0 to 6, Z represents O, S, or an atomic bond, and A represents benzene ring, pyridine ring, and the like).
    Type: Application
    Filed: July 11, 2014
    Publication date: March 23, 2017
    Applicants: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY
    Inventors: Shogo SAKUMA, Kunio KOBAYASHI, Masatoshi USHIODA, Toshiyasu IMAI, Kazuhide INOUE
  • Patent number: 9561235
    Abstract: A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster-associated pain in acute phase: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: February 7, 2017
    Assignees: Kyushu University, Nippon Chemiphar Co., LTD.
    Inventors: Kazuhide Inoue, Makoto Tsuda, Yuta Matsumura
  • Publication number: 20160303073
    Abstract: The present invention provides an agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis of giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma, a local infusion for artery embolization, and an artificial bone, which comprises a substance having a PPAR?-agonistic activity and/or a PPAR? expression-inducing activity as an active ingredient. The agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis, the local infusion for artery embolization, and the artificial bone of the present invention are a radical therapeutic agent or radical therapeutic material that can cause apoptosis in giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma to make the tumor disappear, and can induce differentiation of the tumor into fat cells to make the tumor disappear.
    Type: Application
    Filed: September 25, 2014
    Publication date: October 20, 2016
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Akihiko TAKEUCHI, Hiroyuki TSUCHIYA
  • Patent number: 9463185
    Abstract: A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 11, 2016
    Assignees: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.
    Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue